OncLive® On Air

Episodes

S16 Ep6: FDA Approval Insights: Subcutaneous Amivantamab for EGFR-Mutated NSCLC: With Alexander I. Spira, MD, PhD, FACP, FASCO

February 19, 2026

Subcutaneous amivantamab for EGFR+ NSCLC is a win-win, cutting chair time and infusion reactions with potentially better efficacy.

S16 Ep5: Cases & Conversations™: Unmasking Epithelioid Sarcoma – Enhancing Early Diagnosis and Multidisciplinary Care

February 18, 2026

Experts discuss epithelioid sarcoma, covering diagnostic delays, multidisciplinary care, and treatment sequencing with chemotherapy vs. tazometastat.

S16 Ep4: Comprehensive Ph+ ALL Paradigm Knowledge Informs Frontline Ponatinib Use: With Nicholas Short, MD

February 13, 2026

In Ph+ ALL, ponatinib is the preferred frontline TKI, often in chemotherapy-free regimens with blinatumomab for deeper, durable responses.

S16 Ep3: Third-Line Treatment Selection in mCRC Is Shaped By Recalibration of Patient Priorities and Molecular Retesting: With Christopher Lieu, MD

February 11, 2026

Third-line mCRC treatment shifts from aggressive response to stabilization, guided by patient status, prior toxicities & molecular retesting.

S16 Ep2: “D” is for Diagnosis: Decoding a Difficult Thoracic Malignancy—Piecing Together a Rare Diagnosis, Preparing for Tomorrow’s Treatments

February 11, 2026

Experts decode mesothelioma diagnosis and treatment, comparing nivolumab/ipilimumab vs. chemo-immunotherapy based on histology and patient factors.

S16 Ep1: Targeted Therapies Take Center Stage for Estrogen Receptor–Positive Breast Cancer: With Aditya Bardia, MD, MPH, FASCO

February 10, 2026

Targeted therapies like gerodestrin (Ladera study) are showing superiority in ER+ breast cancer, driving a shift toward personalized care.

S15 Ep50: Bladder Cancer Experts Note Implications of Upfront Enfortumab Vedotin Dose Reduction in Advanced Urothelial Carcinoma: With Ramy Sedhom, MD; Ryan Chow, MD; and Ronac Mamtani, MD, MSCE

February 5, 2026

Rethinking dose intensity: Lower upfront Enfortumab Vedotin doses for urothelial cancer may cut toxicity without impacting overall survival.

S15 Ep49: Innovation, Equity, and the Future of Oncology: World Cancer Day Spotlight With Deb Schrag, MD, MPH

February 4, 2026

ASCO's 2026 president-elect, Dr. Deb Schrag, outlines priorities for oncology: democratizing research, embracing AI, and ensuring an equitable workforce.

S15 Ep48: Multidisciplinary Teams Optimize Surgical and Therapeutic Roles in Advanced CSCC Care: With Eric Whitman, MD; and Vishal Patel, MD, FAAD, FACMS

January 31, 2026

Experts discuss the evolving CSCC paradigm, highlighting neoadjuvant immunotherapy, multidisciplinary teamwork, and personalized medicine.

S15 Ep47: ASCENT-07 Trial Propels Further Questions About the Role of Earlier-Line ADCs in HR+ Metastatic Breast Cancer: With Komal Jhaveri, MD, FACP

January 31, 2026

The ASCENT-07 trial for Sacituzumab Govitecan failed to improve first-line outcomes in HR+ breast cancer, maintaining standard chemo's role.

S15 Ep46: Expanded BTK Inhibitor Research Directs the Evolution of Pirtobrutinib Use in CLL: With Andrew Lipsky, MD

January 31, 2026

Pirtobrutinib's FDA approval in relapsed/refractory CLL expands second-line treatment options, emphasizing personalized sequencing and safety.

S15 Ep45: Early, Reflex Biomarker Testing Is Critical to Optimizing NSCLC Treatment Decisions Across Disease Stages: With Adam Fox, MD, and Cynthia A. Schandl, MD, PhD

January 30, 2026

Early, reflex biomarker testing is crucial in NSCLC. Pathologist-led, coordinated care is key to reducing delays and optimizing treatment.

S15 Ep44: Subcutaneous Isatuximab via On-Body Injector Has Noninferior Efficacy vs IV Delivery in Myeloma: With Sikander Ailawadhi, MD; and Beth Faiman, CNP, PhD

January 30, 2026

Sub-Q Isatuximab via an on-body device is non-inferior to IV for myeloma, proving effective across all body weights and enabling home care.

S15 Ep43: Medical Crossfire®: The Who, When, and How of TROP2-Targeting ADCs, ICIs, and PARP Inhibition in Triple-Negative Breast Cancer

January 30, 2026

Experts discuss pivotal trials for metastatic TNBC, detailing the impact of TROP2 ADCs, ICIs, and PARP inhibitors on evolving treatment.

S15 Ep42: Long-Term Epcoritamab Data Show Durable Responses and Confirmed Safety in LBCL: With Tycel Phillips, MD

January 30, 2026

Long-term epcoritamab data show durable responses (>4 years) and confirmed safety in LBCL, supporting its use as a curative third-line option.

S15 Ep41: Multidisciplinary Breast Cancer Experts Outline Proactive Strategies for Managing Treatment-Related Toxicities: With Neil Iyengar, MD; Heather Moore, CPP, PharmD; and Sarah Donahue, MPH, NP

January 30, 2026

Experts outline proactive, multidisciplinary strategies for managing diarrhea, hyperglycemia, and rash from PI3K/AKT inhibitors in breast cancer.

S15 Ep40: ELEGANT Trial Seeks to Expand Treatment Options for ER+, HER2-Negative Early Breast Cancer: With Aditya Bardia, MD, MPH, FASCO

January 29, 2026

Dr. Bardia discusses the Phase III ELEGANT trial, evaluating elacestrant vs. standard endocrine therapy in high-risk, ER+/HER2- early breast cancer.

S15 Ep39: Novel Targeted Agents Are Poised to Influence MPN Treatment Paradigm: With John O. Mascarenhas, MD

January 29, 2026

Beyond JAK inhibitors: Experts discuss novel targeted agents like CALR and JAK2V617F inhibitors poised to reshape MPN treatment paradigms.

S15 Ep38: Tackling Oncologic Emergencies in Patients Treated With High-Dose Methotrexate

January 29, 2026

Experts discuss managing high-dose methotrexate-induced acute kidney injury, highlighting glucarpidase for rapid clearance and improved recovery.

S15 Ep37: Immuno-Oncology and Novel Cell Therapies Set Transformation in Motion for Gynecologic Oncology: With Ursula A. Matulonis, MD; and Rebecca Porter, MD, PhD

January 28, 2026

Experts discuss immunotherapy's new role in GYN cancers, from the B96 trial in ovarian cancer to novel cell therapies on the horizon.

S14 Ep86: Hot Seat: How Experts Are Integrating the Latest Practice-Changing Data Into Their Breast Cancer Clinics

January 26, 2026

Experts discuss integrating practice-changing data from DESTINY and PATINA trials, focusing on TDXD's expanding role in breast cancer.

S14 Ep85: Medical Crossfire™: Navigating the Expanding Arsenal of Endocrine Therapies for HR+/HER2– Metastatic Breast Cancer – How Can PROTAC ER Degradation Shift the Standard?

January 22, 2026

Experts discuss ctDNA-guided therapy for HR+/HER2- MBC, focusing on ESR1 mutations and the expanding arsenal of next-gen endocrine agents.

S14 Ep84: Cases and Conversations™: Transforming Small Cell Lung Cancer Treatment Through Emerging Evidence and Expert Insights

January 21, 2026

Experts discuss transforming SCLC care with immunotherapy (ADRIATIC trial) in limited stage & new agents like tarlatumab for extensive stage.

S14 Ep83: Hot Seat: Converging Lines in the Management of RAS-Altered Cancers

January 21, 2026

Experts discuss the rise of RAS inhibitors, detailing pivotal data in lung, pancreatic, and GYN cancers transforming this undruggable target.

S14 Ep82: Lisaftoclax Plus Azacitidine May Make New Inroads in Higher-Risk MDS Management: With Guillermo Garcia-Manero, MD

January 20, 2026

Dr. Garcia-Manero discusses the GLORIA-IV trial, evaluating lisaftoclax plus azacitidine for higher-risk MDS as a potential new standard of care.

S14 Ep81: Medical Crossfire® From Frontline to Heavily Pretreated HR+/HER2- Metastatic Breast Cancer: Expert Perspectives on Optimizing the Expanding Treatment Armamentarium

January 20, 2026

Experts discuss optimizing HR+/HER2- metastatic breast cancer care with CDK4/6i, targeted agents, and novel antibody-drug conjugates.

S14 Ep80: Precision in Practice: Advancing Prostate Cancer Care With PSMA-Directed Radioligand Therapy

January 20, 2026

Experts discuss PSMA-targeted radioligand therapy, from advanced PET imaging diagnostics to pivotal clinical trial data and access barriers.

S14 Ep79: Medical Crossfire®: Mastering the Nuances of Early-Stage HR+/HER2- Breast Cancer—Expert Perspectives on Applying Modern Treatment Paradigms

January 19, 2026

Experts debate adjuvant CDK4/6i, PARPi, & ICIs in early-stage HR+/HER2- breast cancer, focusing on MONARCH-E, NATALY, & OlympiA trial data.

S14 Ep78: Emerging CELMoDs Set New Standards for Efficacy and Tolerability in Myeloma: With Rahul Banerjee, MD, FACP

January 16, 2026

Dr. Rahul Banerjee explains how emerging CELMoDs are a new drug class set to replace IMiDs in myeloma, offering superior efficacy and safety.

S14 Ep77: Show Me the Data™: Personalizing First-Line and Maintenance Therapy in HER2+ Metastatic Breast Cancer to Extend Survival and Elevate Quality of Life

January 16, 2026

Experts discuss personalizing HER2+ metastatic breast cancer therapy with data from PATINA, HER2CLIMB-05, and strategies for brain mets.

S14 Ep76: FDA Approval Insights: Epcoritamab Plus Rituximab/Lenalidomide for Relapsed/Refractory Follicular Lymphoma: With Lorenzo Falchi, MD

January 15, 2026

FDA approves Epcoritamab+R² for relapsed follicular lymphoma, establishing a new, highly effective, chemo-free standard based on Epcor FL1 data.

S14 Ep75: FDA Approval Insights: BVd for Relapsed/Refractory Multiple Myeloma: With Surbhi Sidana, MD

January 9, 2026

FDA approves belantamab mafodotin for myeloma, a new community-based option. Key challenges: ocular toxicity management & sequencing with CAR-T.

S14 Ep74: PRRT With 177Lu-Edotreotide Improves Outcomes vs Everolimus in Metastatic GEP-NETs: With Jonathan R. Strosberg, MD

January 7, 2026

COMPETE trial: 177Lu-Edotreotide PRRT shows a 10-month progression-free survival benefit over everolimus in metastatic GEP-NETs.

S14 Ep73: Experts Explore Intersections Between Breast Surgery and Radiation for Comprehensive Care: With Hirsch Matani, MD; Elizabeth Zhang-Velten, MD; and Valentina Bonev, MD, DABS, FACS, FSSO

January 5, 2026

Experts discuss de-escalating breast cancer therapy, emphasizing collaboration between surgery and radiation for personalized, less invasive care.

S14 Ep72: CLL Treatment Paradigm Shifts With Evolving Treatment Sequencing and BTK Inhibition: With Joanna M. Rhodes, MD, MSCE; and Krish Patel, MD

December 31, 2025

Experts discuss the evolving CLL treatment landscape, balancing fixed vs. continuous therapy, patient preference, and sequencing new BTK inhibitors.

S14 Ep71: FDA Approval of Enfortumab Vedotin/Pembrolizumab Redefines Perioperative Care for Cisplatin-Ineligible MIBC: With Christof Vulsteke, MD, PhD

December 31, 2025

FDA-approved Enfortumab Vedotin/Pembrolizumab (EVP) redefines MIBC care, showing huge survival benefits for cisplatin-ineligible patients.

S14 Ep70: Osimertinib Carves a Continuing Role in Perioperative NSCLC Management: With Julia Rotow, MD; and Gavitt Woodard, MD

December 29, 2025

ADAURA, LAURA & NeoADURA trials expand osimertinib's role in perioperative EGFR-mutated NSCLC, making early biomarker testing essential.

S14 Ep69: MRI Techniques Evolve for Glioma Diagnosis, Response Assessment, and Surveillance: With Kathryn S. Nevel, MD; and Michael Veronesi, MD, PhD

December 25, 2025

Experts discuss advanced MRI & PET imaging for gliomas, highlighting how FET PET can clarify ambiguous cases of progression vs. pseudoprogression.

S14 Ep68: ctDNA Testing Opens Avenues for the Future of Breast Oncology: With Jason Mouabbi, MD

December 22, 2025

Dr. Jason Mouabbi discusses ctDNA's transformative role in breast cancer, from screening to predicting recurrence and guiding treatment.

S14 Ep67: Microbiome Profiling Highlights Impact of Butyrate Loss on Post-Transplant Outcomes in Multiple Myeloma: With Pooja M. Phull, MD

December 18, 2025

Gut microbiome profiling reveals that butyrate loss after stem cell transplant worsens multiple myeloma outcomes, highlighting diet's critical role.

S14 Ep66: Ongoing Sigvotatug Vedotin Exploration Highlights Potential for Biomarker Advancement in NSCLC: With Edward S. Kim, MD, MBA; and Jyoti Malhotra, MD, MPH

December 17, 2025

Experts discuss Sigvotatug Vedotin, an ADC targeting the highly prevalent IB6 biomarker in NSCLC, as a potential new second-line standard of care.

S14 Ep65: ASH 2025 LBA BRUIN-CLL 313 Update: Pirtobrutinib vs Bendamustine/Rituximab in 1L CLL

December 17, 2025

ASH 2025 update: Pirtobrutinib shows superior PFS vs. chemoimmunotherapy in frontline CLL, but its place among modern therapies is debated.